Protection assessments indicated that gastrointestinal adverse events, mainly nausea and diarrhea, had been dose-dependent but normally delicate and transient. These conclusions founded the therapeutic window and educated dose range for subsequent Phase 3 trials.第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多